MXPA03001287A - Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses. - Google Patents

Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses.

Info

Publication number
MXPA03001287A
MXPA03001287A MXPA03001287A MXPA03001287A MXPA03001287A MX PA03001287 A MXPA03001287 A MX PA03001287A MX PA03001287 A MXPA03001287 A MX PA03001287A MX PA03001287 A MXPA03001287 A MX PA03001287A MX PA03001287 A MXPA03001287 A MX PA03001287A
Authority
MX
Mexico
Prior art keywords
necroses
tumours
plaques
imaging
representation
Prior art date
Application number
MXPA03001287A
Other languages
Spanish (es)
Inventor
Johannes Platzek
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10040380A external-priority patent/DE10040380B4/en
Application filed by Schering Ag filed Critical Schering Ag
Publication of MXPA03001287A publication Critical patent/MXPA03001287A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MXPA03001287A 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses. MXPA03001287A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10040380A DE10040380B4 (en) 2000-08-11 2000-08-11 MRI contrast agent for visualization of plaque, lymph nodes, infarcted and necrotic tissue or both necrosis and tumors, comprising perfluoroalkylated metal complex having specific micelle forming properties
PCT/EP2001/008498 WO2002013874A2 (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses

Publications (1)

Publication Number Publication Date
MXPA03001287A true MXPA03001287A (en) 2003-10-06

Family

ID=7652860

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001287A MXPA03001287A (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses.

Country Status (26)

Country Link
EP (1) EP1307236A2 (en)
JP (1) JP2004506025A (en)
KR (1) KR20030022387A (en)
CN (1) CN1469757A (en)
AR (1) AR034139A1 (en)
AU (2) AU7754901A (en)
BG (1) BG107542A (en)
BR (1) BR0113188A (en)
CA (1) CA2419223A1 (en)
CZ (1) CZ2003392A3 (en)
DE (1) DE10066210B4 (en)
EE (1) EE200300061A (en)
HR (1) HRP20030173A2 (en)
HU (1) HUP0300736A3 (en)
IL (1) IL154385A0 (en)
MX (1) MXPA03001287A (en)
NO (1) NO20030604L (en)
NZ (1) NZ523932A (en)
PL (1) PL365596A1 (en)
RU (1) RU2290206C2 (en)
SK (1) SK1572003A3 (en)
TW (1) TWI296931B (en)
UA (1) UA82642C2 (en)
WO (1) WO2002013874A2 (en)
YU (1) YU10603A (en)
ZA (1) ZA200301949B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10231799B4 (en) * 2002-07-10 2006-10-05 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast agents in MR imaging for the presentation of intravascular thrombi
US7344704B2 (en) 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
DE102005008309A1 (en) * 2005-02-17 2006-08-24 Schering Ag Pharmaceutical agents containing fluoroalkyl-containing metal complexes and epothilones
DE102006021495A1 (en) * 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Use of metal chelate containing perfluorinated alkyl-residue, chelator-residue and metal ion equivalent to the atomic number, for the production of diagnostic agent for representation of amyloid-containing plaques
US7887835B2 (en) * 2006-09-19 2011-02-15 Fujifilm Corporation Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound
DE102006049821A1 (en) * 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft New, well tolerated metal chelates, for use as radiodiagnostic, radiotherapeutic or NMR and X-ray diagnostic agents, contain chelator and perfluorinated polyethylene glycol residues
DE102007015598A1 (en) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Use of fluorochemical compounds for diagnostic purposes using imaging techniques
JP2011190183A (en) * 2010-03-11 2011-09-29 Noguchi Institute Fluorous sugar-bonded crown ether derivative
US9976072B2 (en) 2014-03-26 2018-05-22 Chevron U.S.A. Inc. Multicarboxylate compositions and method of making the same
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US11104639B2 (en) 2016-09-14 2021-08-31 Daikin Industries, Ltd. Branched fluorine-containing compound
JP7034160B2 (en) 2016-11-28 2022-03-11 バイエル・ファルマ・アクティエンゲゼルシャフト High relaxation gadolinium chelate compound for use in magnetic resonance imaging
PE20211471A1 (en) 2018-11-23 2021-08-05 Bayer Ag FORMULATION OF CONTRAST MEANS AND PROCESS TO PREPARE THEM
CN109867635A (en) * 2019-02-14 2019-06-11 华东师范大学 A kind of T1 type micella magnetic resonance imaging contrast and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19603033A1 (en) * 1996-01-19 1997-07-24 Schering Ag Perfluoroalkyl-containing metal complexes, processes for their preparation and their use in NMR diagnostics
JPH10112939A (en) * 1996-10-07 1998-04-28 Nec Corp Power switching circuit
DE19729013A1 (en) * 1997-07-03 1999-02-04 Schering Ag Oligomeric, perfluoroalkyl-containing compounds, processes for their preparation and their use in NMR diagnostics
US6019959A (en) * 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis

Also Published As

Publication number Publication date
IL154385A0 (en) 2003-09-17
DE10066210B4 (en) 2008-02-28
SK1572003A3 (en) 2003-10-07
HUP0300736A3 (en) 2010-01-28
BG107542A (en) 2003-09-30
JP2004506025A (en) 2004-02-26
HUP0300736A2 (en) 2003-09-29
TWI296931B (en) 2008-05-21
CZ2003392A3 (en) 2003-09-17
CN1469757A (en) 2004-01-21
WO2002013874A2 (en) 2002-02-21
BR0113188A (en) 2003-06-24
NO20030604D0 (en) 2003-02-07
NO20030604L (en) 2003-04-11
NZ523932A (en) 2007-07-27
EP1307236A2 (en) 2003-05-07
AR034139A1 (en) 2004-02-04
CA2419223A1 (en) 2003-02-11
ZA200301949B (en) 2004-12-14
RU2290206C2 (en) 2006-12-27
HRP20030173A2 (en) 2005-04-30
KR20030022387A (en) 2003-03-15
AU2001277549B2 (en) 2007-02-08
WO2002013874A8 (en) 2002-06-13
EE200300061A (en) 2004-12-15
UA82642C2 (en) 2008-05-12
AU7754901A (en) 2002-02-25
YU10603A (en) 2006-05-25
PL365596A1 (en) 2005-01-10

Similar Documents

Publication Publication Date Title
MXPA03001287A (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses.
SI1757606T1 (en) Xanthinderivatives for use as medical agents and the preparation thereof
ZA200306886B (en) Pyrazolopyrimidines as therapeutic agents.
NO20015991D0 (en) Bicyclic polyaminoacid-metal complexes, processes for their preparation and use in medical imaging
GB0109537D0 (en) Well treatment fluids and methods for the use thereof
IL158985A0 (en) Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
EP1578347A4 (en) Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2001277549A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
MXPA03006055A (en) Novel n-phenyl-pyrrol bisphosphane compounds and the metal complexes of the same.
AU2002352799A8 (en) Methods for evaluating drug-resistance gene expression in the cancer patient
ITMI991764A0 (en) NEW METALLIC COMPLEXES USABLE IN CATALYSIS FOR THE CO-POLYMERIZATION OF ALPHA-OLEFINS
ZA200205191B (en) LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.
HUP0400997A3 (en) Multidentate aza ligands able to complex metal ions and the use thereof in diagnostics and therapy
MXPA03004932A (en) Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors.
EP1390689A4 (en) Reducing coherent artifacts in an interferometer
SI1322654T1 (en) Platinum complexes as antitumour agents
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
ZA200400313B (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine.
MXPA03002759A (en) New oxabispidine compound useful in the treatment of cardiac arrhythmias.
AU2003281146A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of intravascular thrombes
HUP0400262A3 (en) Glycopeptides, their preparation and use in the treatment of multiple sclerosis
AU6022701A (en) Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione
EP1435963A4 (en) Reduced toxicity cisplatin formulations and methods for using the same
HUP0100318A3 (en) Salicyli denaminoalcohol derivatives, their chiral copper complexes, their preparations and use of the latter
ZA200604529B (en) Platinum (II) complexes, preparation and use

Legal Events

Date Code Title Description
FG Grant or registration